Neurological disorders Archives

News and Trends 23 Aug 2022

Gate Neurosciences emerges from stealth to tackle CNS diseases

Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases

A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based Abbvie with the hope of targeting neurological disease. This is the second partnership between the companies and offers the option to license agreement which is aimed at discovering, developing and commercializing small molecules that modulate novel G protein-coupled receptor (GPCR) […]

August 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Jul 2022

Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA

A drug to target a rare genetic form of a neurological disease that affects the nerve cells, leading to the loss of everyday functions, could be the first of its kind available if approved. The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) from Massachusetts-based Biogen Inc. for tofersen, an […]

July 28, 2022 - 4 minutesmins - By Liza Laws

News and Trends 27 Jun 2022

Trial for adults with late onset Pompe disease halted due to serious adverse event

The US Food and Drug Administration (FDA) has placed a clinical hold on a trial being run for Astrellas Pharma Inc after one of the participants had a serious adverse event (SAE) of peripheral sensory neuropathy. Astrellas made the announcement after the trial, which is evaluating AT845, an investigational adeno-associated virus (AAV) gene replacement in […]

June 27, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Feb 2022

Fast Stroke Treatments in the Works with TargED’s €39M Series A

Patients with sudden strokes and blood clotting conditions need faster and safer treatments. The Dutch company TargED Biopharmaceuticals has raised a €39M Series A round to fund the development of a fast-acting protein drug that could bridge this gap. Time is of the essence when treating acute ischemic stroke, a condition caused by a blood […]

February 22, 2022 - 5 minutesmins - By Jonathan Smith

Discovering New Therapeutic Targets for Alzheimer’s Disease

Effective therapies for neurodegenerative diseases like Alzheimer’s are urgently needed. But developing new drugs is difficult, time-consuming, and expensive, with a high risk of failure. Strategic partnerships can help biotech companies manage costs and access the latest technologies to drive innovation and advance novel therapy ideas. A serious unmet medical need Finding treatments for neurodegenerative […]

September 22, 2021 - 7 minutesmins - By Julia Kaiser

News and Trends 2 Sep 2021

AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research

An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II results this week, raising tentative hopes for the field of treatments targeting the protein tau. For decades, the major culprit responsible for Alzheimer’s disease was suggested to be the buildup of a protein called amyloid-beta in the brain. Blocking this […]

September 2, 2021 - 5 minutesmins - By Jonathan Smith

psychedelics psychiatric atai gh compass

News and Trends 24 Aug 2021

UK Venture Round Shines Spotlight on Europe’s Psychedelics Scene

The UK has cemented its position as a European hub for psychedelics research following a €68.5M ($80M) Series B round from the startup Beckley Psytech. The Oxford-based Beckley Psytech — founded in 2019 to develop psychedelic treatments for neurological conditions — had originally set the target of its venture capital financing at €43M ($50M). Earlier […]

August 24, 2021 - 4 minutesmins - By Jonathan Smith

News and Trends 8 Jul 2021

The Top European Biotech Funding Rounds in June

While oncology and psychedelics dominated European biotech’s biggest funding rounds last month, startup seed financing focused more on gene therapy and drug discovery. Last month saw some momentous events for Europe’s biotech heavyweights. GSK paid an impressive €524M ($625M) upfront to co-develop an immuno-oncology candidate with iTeos Therapeutics in Belgium. Meanwhile, the German antibody drug […]

July 8, 2021 - 5 minutesmins - By Jonathan Smith

spatial transcriptomics 10x genomics readcoor

In Depth 12 May 2021

Spatial Transcriptomics: A Window into Disease

The emerging spatial transcriptomics field is letting researchers map out gene expression in tumor and brain samples. How could this change the way we treat disease? DNA and RNA sequencing technology has undergone a revolution in the last decade, with companies working to provide ever cheaper and faster ways to explore our genetics. This stride […]

May 12, 2021 - 8 minutesmins - By Jonathan Smith

Best in Biotech 10 Feb 2021

Top Neurotech Startups Unlocking the Brain in Russia

Russia has established itself as a hub for neurotech startups, attracting scientists and business people keen to understand, treat, and repair the human brain. Here are the startups leading the charge of neurotech innovation in Russia. Neurotechnology is a field of research that aims to read and influence the brain. Turns out that neurotech is […]

February 10, 2021 - 6 minutesmins - By Carlos de Rojas

News and Trends 21 Dec 2020

Late-Stage Success Raises Hopes to Tackle Alzheimer’s via Inflammation

Paris-based AB Science has scored a rare late-stage clinical triumph in the Alzheimer’s disease field with a drug that puts brakes on inflammation in the brain. Last week, AB Science reported successful results from a phase IIb/III clinical trial testing its drug masitinib in patients with mild to moderate symptoms of Alzheimer’s. Although the company […]

December 21, 2020 - 5 minutesmins - By Victor Kotsev

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us